A Phase 2 interventional study of Pegcetacoplan (APL-2) and Placebo in Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by Apellis Pharmaceuticals, Inc.. Terminated at 60 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.
Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 3 that started in 2020, is the only one in phase 2, and was the 7th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2016; this study’s year is marked. 3 started in 2020.
This study's enrollment of 249 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 99 across the 9 interventional studies, 132 across the 2 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Apellis Pharmaceuticals, Inc., one of the names counted as Biogen. Under that name alone:
Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
2 of the studies in Amyotrophic Lateral Sclerosis by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07223723BiogenA Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | 2027-05-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered subcutaneously twice weekly
Drug: Pegcetacoplan (APL-2)
Other: Placebo
Complement (C3) Inhibitor
Sterile solution of equal volume to active arm
RTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52
The CAFS scale is a combined endpoint ranking subjects' clinical outcomes based on ALS Functional Rating Scale-Revised (ALSFRS-R-described below) and survival time. For ALSFRS-R, 12 functions were rated on 5-point ordinal rating scales (0 to 4) with a total score range of 0-48 (sum of all 12 items); higher score indicated better functioning. For survival time, longer the subject survives indicated better outcome. Each subject's outcome was compared to every other subject outcome in trial in series of pairwise comparisons, summed scores (sum of comparisons \[+1 {better}, 0 {tie}, -1 {worse}\]) were ranked and ranged from 001-247 (number of subjects in modified \[m\]ITT population).Reported values are the least squares mean rank scores in each group for the composite endpoint. Higher rank indicated better outcome.
Time frame: Week 52
RTP: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.
Time frame: From first dose of study drug (Day 1) up to 56 days post last dose of study drug, approximately 60 weeks
OLP: Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.
Time frame: From first dose of study drug (Week 52) up to 56 days post last dose of study drug, approximately 60 weeks
RTP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS) up to Week 52
The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of suicidal ideation (SI) and suicidal behavior (SB).C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale: 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Day 1) up to Week 52
OLP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale up to Week 104
The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of SI and SB.C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale:1 (preparatory acts or behavior),2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration in OLP.
Time frame: From Baseline (Week 52) up to Week 104
RTP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score at Week 52
The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Least squares mean is presented here. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Day 1) and Week 52
RTP: Change From Baseline in Percent Predicted Slow Vital Capacity (%SVC) at Week 52
SVC is a pulmonary function test and predictor of functional loss in ALS. It was conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Day 1) and Week 52
RTP: Change From Baseline in Muscle Strength at Week 52
Muscle strength was measured using handheld dynamometry (HHD) and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Day 1) and Week 52
RTP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 52
Subjects with an event (that is, either death or permanent tracheostomy or permanent assisted ventilation) in RTP are reported.
Time frame: Baseline (Day 1) up to Week 52
RTP: Change From Baseline in ALS Assessment Questionnaire (ALSAQ)-40 at Week 52
The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related quality of life (QoL) over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was calculated by adding the 5 dimension scores; least squares mean is presented here. Higher scores indicated worse QoL.
Time frame: Baseline (Day 1) and Week 52
OLP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score at Week 104
The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Mean is presented here. Baseline was defined as the last observed value for the efficacy assessment prior to taking the first dose of study drug in OLP.
Time frame: Baseline (Week 52) and Week 104
OLP: Change From Baseline in Percent Predicted Slow Vital Capacity at Week 104
SVC is a pulmonary function test and predictor of functional loss in ALS. It was planned to be conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Week 52) and Week 104
OLP: Change From Baseline in Muscle Strength at Week 104
Muscle strength was planned to be measured using HHD and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Time frame: Baseline (Week 52) and Week 104
OLP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 104
Subjects with an event of death are reported. Subjects were planned to be assessed for permanent tracheostomy or permanent assisted ventilation in OLP; however, that data was not collected as study was terminated early.
Time frame: Baseline (Week 52) and Week 104
OLP: Change From Baseline in ALS Assessment Questionnaire-40 at Week 104
The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related QoL over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was planned to be calculated by adding the 5 dimension scores. Higher scores would have indicated worse QoL.
Time frame: Baseline (Week 52) and Week 104
Number of Subjects With an Event of Death During the Study
Total number of subjects who died in the study are reported.
Time frame: RTP: Baseline (Day 1) up to Week 52; OLP: Baseline (Week 52) up to Week 104
This Phase 2, placebo-controlled study was conducted in subjects diagnosed with amyotrophic lateral sclerosis (ALS). A total of 249 subjects were randomized in a 2:1 ratio to either receive pegcetacoplan or placebo.
| Milestone | RTP: Pegcetacoplan | RTP: Placebo | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|---|---|
| Started | 169 | 80 | 0 | 0 |
| Completed | 99 | 51 | 0 | 0 |
| Not completed | 70 | 29 | 0 | 0 |
| Withdrew: Adverse event | 4 | 3 | 0 | 0 |
| Withdrew: Death | 24 | 9 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 7 | 5 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 25 | 11 | 0 | 0 |
| Withdrew: Other | 2 | 0 | 0 | 0 |
| Milestone | RTP: Pegcetacoplan | RTP: Placebo | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|---|---|
| Started | 0 | 0 | 97 | 50 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 97 | 50 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 19 | 12 |
| Withdrew: Sponsor request | 0 | 0 | 63 | 31 |
| Withdrew: Physician decision | 0 | 0 | 3 | 1 |
| Withdrew: Death | 0 | 0 | 10 | 6 |
The CAFS scale is a combined endpoint ranking subjects' clinical outcomes based on ALS Functional Rating Scale-Revised (ALSFRS-R-described below) and survival time. For ALSFRS-R, 12 functions were rated on 5-point ordinal rating scales (0 to 4) with a total score range of 0-48 (sum of all 12 items); higher score indicated better functioning. For survival time, longer the subject survives indicated better outcome. Each subject's outcome was compared to every other subject outcome in trial in series of pairwise comparisons, summed scores (sum of comparisons \[+1 {better}, 0 {tie}, -1 {worse}\]) were ranked and ranged from 001-247 (number of subjects in modified \[m\]ITT population).Reported values are the least squares mean rank scores in each group for the composite endpoint. Higher rank indicated better outcome.
| score on a scale | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| RTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52 | 123.0 ± 4.71 | 126.0 ± 6.89 |
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.
| Participants | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| TEAEs | 137 | 61 |
| TESAEs | 57 | 27 |
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.
| Participants | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|
| TEAEs | 54 | 33 |
| TESAEs | 24 | 14 |
The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of suicidal ideation (SI) and suicidal behavior (SB).C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale: 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration.
| Participants | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| SI only | 16 | 6 |
| SB only | 0 | 0 |
| SI and SB | 1 | 0 |
The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of SI and SB.C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale:1 (preparatory acts or behavior),2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration in OLP.
| Participants | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|
| SI only | 11 | 3 |
| SB only | 0 | 0 |
| SI and SB | 1 | 0 |
The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Least squares mean is presented here. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| score on a scale | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| RTP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score at Week 52 | -16.5 ± 0.81 | -15.8 ± 1.20 |
SVC is a pulmonary function test and predictor of functional loss in ALS. It was conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| percentage of predicted SVC | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| RTP: Change From Baseline in Percent Predicted Slow Vital Capacity (%SVC) at Week 52 | -39.2 ± 2.30 | -32.6 ± 3.17 |
Muscle strength was measured using handheld dynamometry (HHD) and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
| pounds | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| RTP: Change From Baseline in Muscle Strength at Week 52 | -0.78 ± 0.06 | -0.59 ± 0.10 |
Subjects with an event (that is, either death or permanent tracheostomy or permanent assisted ventilation) in RTP are reported.
| Participants | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| RTP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 52 | 42 | 27 |
The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related quality of life (QoL) over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was calculated by adding the 5 dimension scores; least squares mean is presented here. Higher scores indicated worse QoL.
| score on a scale | RTP: Pegcetacoplan | RTP: Placebo |
|---|---|---|
| RTP: Change From Baseline in ALS Assessment Questionnaire (ALSAQ)-40 at Week 52 | 31.3 ± 1.35 | 24.8 ± 1.94 |
The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Mean is presented here. Baseline was defined as the last observed value for the efficacy assessment prior to taking the first dose of study drug in OLP.
| score on a scale | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|
| OLP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score at Week 104 | -19.0 ± 10.82 | -28.0 |
SVC is a pulmonary function test and predictor of functional loss in ALS. It was planned to be conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
No measurements were reported for this outcome.
Muscle strength was planned to be measured using HHD and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
No measurements were reported for this outcome.
Subjects with an event of death are reported. Subjects were planned to be assessed for permanent tracheostomy or permanent assisted ventilation in OLP; however, that data was not collected as study was terminated early.
| Participants | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|
| OLP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 104 | 10 | 6 |
The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related QoL over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was planned to be calculated by adding the 5 dimension scores. Higher scores would have indicated worse QoL.
No measurements were reported for this outcome.
Total number of subjects who died in the study are reported.
| Participants | RTP: Pegcetacoplan | RTP: Placebo | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|---|---|
| Number of Subjects With an Event of Death During the Study | 26 | 11 | 10 | 6 |
Collected over TEAEs, TESAEs and deaths were collected from first dose of study drug (RTP: Day 1/OLP: Week 52) up to 56 days post last dose of study drug, approximately 60 weeks each for RTP and OLP.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RTP: Pegcetacoplan | 26/169 (15.4%) | 57/169 (33.7%) | 124/169 (73.4%) |
| RTP: Placebo | 11/80 (13.8%) | 27/80 (33.8%) | 55/80 (68.8%) |
| OLP: Pegcetacoplan/Pegcetacoplan | 10/97 (10.3%) | 24/97 (24.7%) | 31/97 (32%) |
| OLP: Placebo/Pegcetacoplan | 6/50 (12%) | 14/50 (28%) | 20/50 (40%) |
| Event | RTP: Pegcetacoplan | RTP: Placebo | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|---|---|
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 13/169 | 7/80 | 4/97 | 3/50 |
| Covid-19Infections and infestations | 7/169 | 2/80 | 0/97 | 1/50 |
| Pneumonia AspirationRespiratory, thoracic and mediastinal disorders | 7/169 | 2/80 | 4/97 | 1/50 |
| Pneumonia BacterialInfections and infestations | 0/169 | 0/80 | 0/97 | 2/50 |
| UrosepsisInfections and infestations | 0/169 | 0/80 | 0/97 | 2/50 |
| Amyotrophic Lateral SclerosisNervous system disorders | 6/169 | 3/80 | 0/97 | 2/50 |
| DysphagiaGastrointestinal disorders | 3/169 | 3/80 | 1/97 | 0/50 |
| SepsisInfections and infestations | 0/169 | 0/80 | 3/97 | 0/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/169 | 2/80 | 1/97 | 0/50 |
| PneumoniaInfections and infestations | 2/169 | 2/80 | 2/97 | 0/50 |
| Event | RTP: Pegcetacoplan | RTP: Placebo | OLP: Pegcetacoplan/Pegcetacoplan | OLP: Placebo/Pegcetacoplan |
|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 37/169 | 14/80 | 6/97 | 1/50 |
| COVID-19Infections and infestations | 28/169 | 13/80 | 6/97 | 1/50 |
| ConstipationGastrointestinal disorders | 12/169 | 7/80 | 5/97 | 1/50 |
| HypertensionVascular disorders | 3/169 | 5/80 | 1/97 | 4/50 |
| PneumoniaInfections and infestations | 0/169 | 0/80 | 4/97 | 4/50 |
| DiarrhoeaGastrointestinal disorders | 10/169 | 5/80 | 0/97 | 0/50 |
| Urinary Tract InfectionInfections and infestations | 6/169 | 5/80 | 1/97 | 3/50 |
| InsomniaPsychiatric disorders | 8/169 | 5/80 | 0/97 | 0/50 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/169 | 5/80 | 0/97 | 0/50 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/169 | 0/80 | 2/97 | 3/50 |
The intent-to-treat (ITT) population included all randomized subjects who received at least 1 dose of randomized treatment (pegcetacoplan or placebo).
| Age, Continuous(years) | RTP: Pegcetacoplan | RTP: Placebo | Total |
|---|---|---|---|
| Mean | 57.0 ± 12.47 | 57.7 ± 11.02 | 57.2 ± 12.01 |
| Sex: Female, Male(Participants) | RTP: Pegcetacoplan | RTP: Placebo | Total |
|---|---|---|---|
| Female | 64 | 25 | 89 |
| Male | 105 | 55 | 160 |
| Ethnicity (NIH/OMB)(Participants) | RTP: Pegcetacoplan | RTP: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 15 | 42 |
| Not Hispanic or Latino | 124 | 62 | 186 |
| Unknown or Not Reported | 18 | 3 | 21 |
| Race/Ethnicity, Customized(Participants) | RTP: Pegcetacoplan | RTP: Placebo | Total |
|---|---|---|---|
| Caucasian | 130 | 67 | 197 |
| Black or African American | 0 | 0 | 0 |
| North East Asian | 14 | 6 | 20 |
| South East Asian | 0 | 0 | 0 |
| Other | 13 | 5 | 18 |
| Unknown | 12 | 2 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2020 to primary completion in Mar 2023, 30 months.
Results were first posted in Apr 2025, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcetacoplan
Amyotrophic Lateral Sclerosis →
Apellis Pharmaceuticals, Inc. →